Literature DB >> 29953816

Formulation and Molecular Dynamics Simulations of a Fusidic Acid Nanosuspension for Simultaneously Enhancing Solubility and Antibacterial Activity.

Calvin A Omolo1, Rahul S Kalhapure1,2, Nikhil Agrawal1, Sanjeev Rambharose1,3, Chunderika Mocktar1, Thirumala Govender1.   

Abstract

The aim of the present study was to formulate a nanosuspension (FA-NS) of fusidic acid (FA) to enhance its aqueous solubility and antibacterial activity. The nanosuspension was characterized using various in vitro, in silico, and in vivo techniques. The size, polydispersity index, and zeta potential of the optimized FA-NS were 265 ± 2.25 nm, 0.158 ± 0.026, and -16.9 ± 0.794 mV, respectively. The molecular dynamics simulation of FA and Poloxamer-188 showed an interaction and binding energy of -74.42 kJ/mol and -49.764 ± 1.298 kJ/mol, respectively, with van der Waals interactions playing a major role in the spontaneous binding. There was an 8-fold increase in the solubility of FA in a nanosuspension compared to the bare drug. The MTT assays showed a cell viability of 75-100% confirming the nontoxic nature of FA-NS. In vitro antibacterial activity revealed a 16- and 18-fold enhanced activity against Staphylococcus aureus (SA) and methicillin-resistant SA (MRSA), respectively, when compared to bare FA. Flowcytometry showed that MRSA cells treated with FA-NS had almost twice the percentage of dead bacteria in the population, despite having an 8-fold lower MIC in comparison to the bare drug. The in vivo skin-infected mice showed a 76-fold reduction in the MRSA load for the FA-NS treated group compared to that of the bare FA. These results show that the nanosuspension of antibiotics can enhance their solubility and antibacterial activity simultaneously.

Entities:  

Keywords:  MRSA; enhanced antibacterial activity; improved solubility; molecular dynamics; nanosuspension

Mesh:

Substances:

Year:  2018        PMID: 29953816     DOI: 10.1021/acs.molpharmaceut.8b00505

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  4 in total

Review 1.  Recent Advances in Oral Nano-Antibiotics for Bacterial Infection Therapy.

Authors:  Ze-Liang Wu; Jun Zhao; Rong Xu
Journal:  Int J Nanomedicine       Date:  2020-12-01

Review 2.  Nanotechnology Fundamentals Applied to Clinical Infectious Diseases and Public Health.

Authors:  Ellis Tobin; Sara Brenner
Journal:  Open Forum Infect Dis       Date:  2021-11-20       Impact factor: 3.835

3.  Nanobiotic formulations as promising advances for combating MRSA resistance: susceptibilities and post-antibiotic effects of clindamycin, doxycycline, and linezolid.

Authors:  Mennatallah A Mohamed; Maha Nasr; Walid F Elkhatib; Wafaa N Eltayeb; Aliaa A Elshamy; Gharieb S El-Sayyad
Journal:  RSC Adv       Date:  2021-12-13       Impact factor: 4.036

4.  Synthesis, Characterization and In Vitro Evaluation of Chitosan Nanoparticles Physically Admixed with Lactose Microspheres for Pulmonary Delivery of Montelukast.

Authors:  Faqir Ullah; Kifayat Ullah Shah; Shefaat Ullah Shah; Asif Nawaz; Touseef Nawaz; Kamran Ahmad Khan; Raed F Alserihi; Hossam H Tayeb; Shams Tabrez; Mulham Alfatama
Journal:  Polymers (Basel)       Date:  2022-08-29       Impact factor: 4.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.